Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study

Yongkang Xu, Shumin Fu, Kan Liu, Ye Mao, Jianbing Wu Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, People’s Republic of ChinaCorrespondence: Jianbing Wu, Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, People’s Repub...

Full description

Bibliographic Details
Main Authors: Xu Y, Fu S, Liu K, Mao Y, Wu J
Format: Article
Language:English
Published: Dove Medical Press 2023-10-01
Series:Therapeutics and Clinical Risk Management
Subjects:
hepatocellular carcinoma
lenvatinib
pd-1 inhibitors
regorafenib
sorafenib
overall survival
Online Access:https://www.dovepress.com/lenvatinib-plus-pd-1-inhibitors-versus-regorafenib-in-patients-with-ad-peer-reviewed-fulltext-article-TCRM

Internet

https://www.dovepress.com/lenvatinib-plus-pd-1-inhibitors-versus-regorafenib-in-patients-with-ad-peer-reviewed-fulltext-article-TCRM

Similar Items